CTRI/2009/091/000885已完成3 期
Randomized, Phase III-b, Multi-centre, Open-label, Parallel study of Enoxaparin (low molecular weight heparin) given concomitantly with chemotherapy vs chemotherapy alone in patients with inoperable gastric and gastro-oesophageal cancer.
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 740
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Signed written informed consent
- •2. Male or Female of age 18-75 years
- •3. Histologically confirmed gastric or gastro-oesophageal carcinoma.
- •4. Adenocarcinoma of the stomach stage III or IV considered inoperable at presentation.
- •5. ECOG performance status < 1
- •6. Criteria for chemotherapy fulfilled (haematological, hepatic, renal).
- •7. Ability to receive daily injection (self-injection or by patient relative).
- •8. Urine-Pregnancy test negative.
- •9. Consent to the use of Contraceptive for women of child bearing age group
排除标准
- •1. History of previous malignancy within the previous 5 years (except curatively treated carcinoma in situ of the uterine cervix, or basal cell carcinoma of the skin), or concomitant malignancy.
- •2. Prior treatment with chemotherapy or radiotherapy if relapse less than 6 months
- •3. Non-epithelial gastric tumours, borderline tumours.
- •4. Medically unstable patients, including but not limited to those with active infection, acute hepatitis, gastrointestinal bleeding, uncontrolled cardiac arrhythmias, interstitial lung disease, inflammatory bowel disease, uncontrolled angina, uncontrolled hypercalcaemia, uncompensated congestive heart failure, uncontrolled diabetes, persistent renal failure, dementia, seizures, superior vena cava syndrome.
- •5. Persistent renal failure (persistent value of the calculated creatinine clearance < 30 mL/min defined as a documented value < 30 mL/min on at least 2 occasions > 3 days prior entry into the study).
- •6. Prosthetic heart valves.
- •7. Any evidence of active bleeding disorder or risk of bleeding identified on fibroscopy done as a routine investigation before the consent for the trial. Fibroscopy is not mandatory to be done for the trial
- •8. Current, objectively-verified DVT, PE or other clinically significant thrombosis.
- •9. Documented previous episode of heparin-induced thrombocytopenia and/or thrombosis (HIT, HAT, or HITTS).
- •10. Contraindications to anticoagulation
- •Coagulopathies (acquired or inherited)
- •Prior history of cerebral hemorrhage or neurosurgery within the previous month
- •Bacterial endocarditis
- •Uncontrolled arterial hypertension (systolic BP >200 mmHg or diastolic BP >110 mmHg) at 2 successive readings
- •Haemostatic abnormalities: circulating anticoagulant, baseline platelet count <50 000/mm3, activated partial thromboplastin time (aPTT) value 1.5 x the upper limit of normal, or International Normalized Ratio (INR) >1.5. The laboratory test valid would be no earlier than 14 days for this criterion.
- •Indication for thrombolytic therapy
- •Any long-term anticoagulant therapy for medical condition.
- •11. Immunocompromised subjects, such as subjects with known HIV and those who have either had an AIDS-defining condition (e.g. Kaposi?s sarcoma, Pneumocystitis carinii pneumonia) or have CD4 + T-lymphocyte count < 200 /mm3.
- •12. Known hypersensitivity to heparin, or LMWH, or pork derived products.
- •13. Body weight >100 kg.
- •14. Pregnant or lactating women.
- •15. Women of childbearing potential not protected by effective contraceptive method of birth control and/or who are unwilling to be tested for pregnancy (pregnancy status should be checked by serum or urine pregnancy testing prior to exposure to the investigational product
- •16. Participation in another clinical trial (study medications / study devices) within the previous 30 days. (Surgical trials are allowed).
- •17. Psychiatric disorders of altered mentation that would preclude understanding of the informed consent process.
- •18. Psychological, familial, sociological, or geographical conditions, which do not permit treatment and/or medical follow-up required to comply with the study protocol
研究者
相似试验
进行中（未招募）
不适用
Phase II/III, Multicenter, Open-label, Randomized Study Comparing Autologous Intravesical Macrophage Cell Therapy (Bexidem”) to Intravesical BCG-Therapy in Patients With Superficial Papillary Bladder Cancer Who Have Undergone Complete Transurethral ResectioBLADDER CANCER AFTER TRANSURETRHAL RESECTIOEUCTR2004-003699-13-ESINMUNO DESIGNED MOLECULES (IDM)650
进行中（未招募）
3 期
Clinical trial/study for lung cancer patients with ROS1 positiveCTRI/2022/04/041861F HoffmannLa Roche Ltd
进行中（未招募）
不适用
A Phase III Study of MEDI4736 versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancerocally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV)MedDRA version: 17.0Level: LLTClassification code 10066490Term: Progression of non-small cell lung cancerSystem Organ Class: 100000004864MedDRA version: 17.0Level: LLTClassification code 10029514Term: Non-small cell lung cancer NOSSystem Organ Class: 100000004864EUCTR2014-000338-46-ESAstraZeneca AB770
进行中（未招募）
1 期
A Phase III Study of MEDI4736 versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancerocally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV)MedDRA version: 17.0Level: LLTClassification code 10066490Term: Progression of non-small cell lung cancerSystem Organ Class: 100000004864MedDRA version: 17.0Level: LLTClassification code 10029514Term: Non-small cell lung cancer NOSSystem Organ Class: 100000004864EUCTR2014-000338-46-GRAstraZeneca AB770
进行中（未招募）
1 期
Clinical study to evaluate the efficacy of fosfomycin vs meropenem in the treatment of bacteremia due to Escherichia coli (general infection caused by a specific bacteria).Bacteremic urinary tract infection by Escherichia coli extended spectrum beta-lactamase (ESBL).MedDRA version: 16.1 Level: PT Classification code 10052238 Term: Escherichia urinary tract infection System Organ Class: 10021881 - Infections and infestationsEUCTR2013-002922-21-ESFISEVI198